Four non–vitamin K antagonist oral anticoagulants (NOACs), including the direct thrombin
inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban …

Although the direct oral anticoagulants (DOACs) do not require routine monitoring and
reduce bleeding compared with warfarin, there are special circumstances in which …

Direct oral anticoagulants (DOACs) are a new class of anticoagulants that directly inhibit
either thrombin or factor Xa in the coagulation cascade. They are being increasingly used …

The use of direct oral anticoagulants over traditional warfarin has increased in the United
States over the past 10 years because of advantages such as ease of use, predictable …

The limits of traditional anticoagulants, such as heparin and warfarin, have prompted the
search for new agents for prophylaxis and treatment of arterial and venous …

The main advantage of the direct oral anticoagulants over vitamin K antagonists is reduced
rates of major bleeding, especially intracranial hemorrhage. While use of different clotting …

In recent years, small oral compounds that specifically block activated coagulation factor X
(FXa) or thrombin (FIIa) have become alternatives to the anticoagulants that had been used …

Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared
to vitamin K antagonists (VKAs) for the prevention and treatment of venous …

INTRODUCTION—The use of any anticoagulant is associated with an increased risk of
bleeding, and bleeding complications can be life-threatening. Management of bleeding in …

Direct oral anticoagulants (DOACs) are approved for multiple thromboembolic disorders and
provide advantages over existing agents. As with all anticoagulants, management protocols …